Bisoprolol (Concor)

Subscribe to Selected New Research on Bisoprolol

358 relevant articles (46 outcomes, 129 trials/studies) found for this Drug

Description: A cardioselective beta-1-adrenergic blocker. It is effective in the management of hypertension and angina pectoris.

Also Known As:

Concor; Bisoprolol Fumarate; Bisoprolol Fumarate (1:1) Salt, (+-)-Isomer; Bisoprolol Fumarate (2:1) Salt, (+-)-Isomer; Bisoprolol Hydrochloride; Bisoprolol Methanesulfonate Salt; Bisoprolol, (+-)-Isomer; Bisoprolol, (-)-Isomer; Bisoprolol, Fumarate (1:1) Salt; Bisoprolol, Fumarate (2:1) Salt; CL-297939; EMD-33512; CL 297939; CL297939; EMD 33512; EMD33512; Fumarate, Bisoprolol; Hydrochloride, Bisoprolol; 2-Propanol, 1-(4-((2-(1-methylethoxy)ethoxy)methyl)phenoxy)-3-((1-methylethyl)amino)-

Relationship Network

Drug Context: Research Results

Organic Chemicals: 40

Amines: 1234

Amino Alcohols: 10

Propanolamines: 2

Phenoxypropanolamines: 1

Experts

1.	Krum, Henry: 4 articles (10/2008 - 02/2004)
2.	Willenheimer, Ronnie: 3 articles (10/2008 - 06/2004)
3.	Follath, Ferenc: 3 articles (09/2008 - 06/2004)
4.	Lechat, Philippe: 3 articles (10/2005 - 02/2002)
5.	van Veldhuisen, Dirk J: 2 articles (10/2008 - 10/2005)
6.	Gustafsson, Finn: 2 articles (02/2008 - 01/2004)
7.	Lip, Gregory Y H: 2 articles (12/2007 - 10/2003)
8.	Ponikowski, Piotr: 2 articles (10/2005 - 06/2004)
9.	Erdmann, Erland: 2 articles (10/2005 - 06/2004)
10.	Silke, Bernard: 2 articles (10/2005 - 06/2004)

Related Diseases

1.	Heart Failure 12/01/2005 - "Specifically, the Cardiac Insufficiency Bisoprolol Study II has shown a significant reduction in mortality and morbidity among patients with moderate to severe chronic heart failure treated with bisoprolol" 01/01/2003 - "RESULTS: The use of bisoprolol was associated with significant improvement of heart failure functional class, lowering of heart rate (by 14%, p<0.01), elevation of systolic blood pressure (by 7.2+/-12.3 mm Hg, p<0.01) and increase of walking distance (by 30.1+/-29.0 m, p<0.01)" 01/01/1998 - "Adjuvant therapy with bisoprolol was not only clinically beneficial for the patient with heart failure but was also economically advantageous." 09/01/2003 - "CONCLUSIONS: This is the first study in Spain to show that bisoprolol can be used effectively at the maximum recommended doses, for the outpatient treatment of heart failure." 12/15/2000 - "CONCLUSION: The use of bisoprolol in the therapy of chronic heart failure is not only clinically effective, it also saves net costs." Order ALL the reference details at left...
2.	Hypertension (High Blood Pressure) 01/01/1990 - "Long-term efficacy and safety of the beta1-selective adrenoceptor-blocking agent bisoprolol was investigated in 164 patients with mild to moderate essential hypertension who had already been treated successfully with bisoprolol once daily for 1 year in preceding studies" 01/01/2006 - "It has been reported that bisoprolol is effective in reducing blood pressure and has beneficial cardiac effects in patients with hypertension" 01/01/1990 - "Bisoprolol proved in this study to be an effective and safe antihypertensive agent when given to patients with mild to moderate hypertension for 8 weeks." 11/01/2007 - "Data presented here indicate that bisoprolol 5 mg given once daily to treat patients with mild to moderate essential hypertension is effective and safe for treatment and for preservation of renal performance when given on a medium-term basis." 11/01/2007 - "This study was designed to evaluate the antihypertensive efficacy and effects on renal hemodynamics and function of bisoprolol during medium-term (6 mo) treatment of patients with mild to moderate essential hypertension" Order ALL the reference details at left...
3.	Angina Pectoris 01/01/1995 - "The Total Ischemic Burden Bisoprolol Study (TIBBS) was a randomized double-blind controlled study with two parallel groups; 330 patients from 30 centers in seven European countries with stable angina pectoris, a positive exercise test and more than two transient ischemic episodes during 48 h of Holter monitoring (central evaluation) were included" 01/01/1990 - "The purpose of the study was to assess the efficacy and tolerance of the beta1-selective beta-adrenoceptor-blocking agent bisoprolol in patients with chronic stable angina pectoris" 09/01/1993 - "Bisoprolol is suitable for use in hypertensive patients with associated diseases, in particular angina pectoris and impaired rhythm." 01/01/1990 - "Bisoprolol in the treatment of chronic stable angina pectoris." 01/01/1990 - "Bisoprolol is a new beta1-selective beta-blocker with a clear 24-h duration of action regarding symptoms and improvement of exercise capacity in patients with stable exercise-induced angina pectoris" Order ALL the reference details at left...
4.	Myocardial Infarction 03/01/1998 - "Late bisoprolol treatment improved stroke volume index, and early bisoprolol treatment reduced diastolic wall stress, in rats with a large myocardial infarct" 12/09/1999 - "Thus, the primary study end point of death from cardiac causes or nonfatal myocardial infarction occurred in 2 patients in the bisoprolol group (3.4 percent) and 18 patients in the standard-care group (34 percent, P<0.001)" 03/01/1991 - "Two pilot open studies were performed up to now with IV bisoprolol in acute myocardial infarction (MI)" 01/01/1990 - "This study shows that combined use of bisoprolol and a class I antiarrhythmic drug appears to be safe in patients with ventricular tachyarrhythrhythmias late after myocardial infarction." 03/01/2000 - "Bisoprolol prevents mortality and myocardial infarction after vascular surgery." Order ALL the reference details at left...
5.	Cardiomyopathies (Cardiomyopathy) 06/01/1999 - "Betablockers, especially bisoprolol in the CIBIS-I trial, also seem to be more effective in non-ischaemic cardiomyopathy" 05/01/2000 - "In the animal model of autoimmune cardiomyopathy induced by active immunization of rabbits with beta 1-adrenoceptor peptide, bisoprolol was given at a dose of 3 mg/day throughout the study period" 10/01/1997 - "In the Cardiac Insufficiency Bisoprolol Study (CIBIS), in patients with idiopathic as well as ischaemic cardiomyopathy, there was a nonsignificant 20% reduction in mortality" 01/01/1996 - "Recently, several randomised controlled studies have demonstrated improvement in survival of patients with non ischemic cardiomyopathy (Bisoprolol, Metoprolol, Carvedilol) and ischemic cardiomyopathy (Carvedilol)" Order ALL the reference details at left...

Related Drugs and Biologics

1.	Metoprolol (Lopressor)
2.	carvedilol (Coreg)
3.	Atenolol (Tenormin)
4.	nebivolol
5.	Nifedipine (Adalat)
6.	Diuretics
7.	Enalapril
8.	Hydrochlorothiazide (Esidrix)
9.	Amlodipine (Norvasc)
10.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)

Related Therapies and Procedures

1.	Aftercare (After-Treatment)
2.	Electric Countershock (Cardioversion)
3.	Ligation
4.	Lasers (Laser)
5.	Anesthesia

Best Treatments:
Research Summary Report
on Heart Failure

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 2627 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>